New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
05:55 EDTAGN, AGN, SE, SE, NYX, NYX, K, K, EL, EL, EMR, EMR, ETN, ETN, DO, DO, DLPH, DLPH, CSC, CSC, CAH, CAH, BDX, BDX, ADP, ADP, ADM, ADM, TE, TECompanies reporting Before the Market Open on Tuesday, February 5
Notable companies reporting before the opening bell include Allergan (AGN), Archer Daniels Midland (ADM), Automatic Data Processing (ADP), Becton Dickinson and Co (BDX), Cardinal Health (CAH), Computer Sciences (CSC), Delphi Automotive (DLPH), Diamond Offshore Drilling (DO), Eaton (ETN), Emerson Electric (EMR), Estee Lauder Companies (EL), Kellogg (K), NYSE Euronext (NYX), Spectra Energy (SE) and TECO Energy (TE).
News For AGN;ADM;ADP;BDX;CAH;CSC;DLPH;DO;ETN;EMR;EL;K;NYX;SE;TE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 19, 2015
08:13 EDTDLPHDetroit Economic Club to host a luncheon meeting
Subscribe for More Information
07:40 EDTAGNActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
05:39 EDTDLPHDelphi Automotive agrees to sell thermal business to MAHLE
Delphi Automotive announced that it has entered into a definitive agreement to sell its wholly-owned thermal business to MAHLE GmbH for cash consideration of approximately $727M, subject to closing adjustments, which represents an implied EV/LTM EBITDA multiple of approximately 9.5x. The transaction is expected to close in the third quarter of 2015, subject to regulatory approvals. Proceeds from the transaction will be used to fund growth initiatives, including acquisitions and share repurchases. Delphi and MAHLE also signed a separate letter of intent to sell Delphi’s stake in Shanghai Delphi Automotive Air-Conditioning System. Proceeds from this transaction will be in addition to the $727M paid for the wholly-owned operations. Delphi’s Thermal division had 2014 revenues of $1.6B, with approximately 6,700 employees and 13 plants globally. The results of operations of the Thermal division business will be reported as discontinued operations beginning in the first quarter of 2015.
February 18, 2015
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
10:05 EDTDOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
09:14 EDTKKellogg says goal is to drive business into sustainable top line growth
Management stated that FY15 guidance is "pragmatic" and a step in the direction of growth. The company expects to return to growth in FY16 and beyond. Chief Growth Officer Paul Norman says the company needs to follow consumer trends and that the company needs to adapt to wellness trends. CFO Ron Dissinger stated that there is no change in the guidance provided last week and that Project K remains on track. Project K investments include innovation and renovation of food and packaging, geographic expansion, as well as channel expansion and growth. The company is aware that some consumers are looking for gluten-free options and the company has gluten-free products in its portfolio. Comments made during 2015 CAGNY Conference presentation.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:56 EDTDODiamond Offshore initiated with an Underperform at BMO Capital
Target $29.
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
February 17, 2015
18:17 EDTCSCJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:15 EDTBDXBecton Dickinson management to meet with William Blair
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
07:15 EDTADM, KConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
February 16, 2015
15:17 EDTDOTransocean slashes dividend to 60c from $3.00, says CEO leaving
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use